APC 100
Alternative Names: APC-100; CPC-100Latest Information Update: 04 Dec 2017
At a glance
- Originator Wisconsin Alumni Research Foundation
- Developer Adamis Pharmaceuticals Corporation
- Class Anti-inflammatories; Antiandrogens; Antineoplastics; Small molecules
- Mechanism of Action Androgen receptor antagonists; Antioxidants; Reactive oxygen species inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 19 Jan 2015 APC 100 is still in a phase I/IIa trial for Prostate cancer in USA
- 21 Aug 2013 APC 100 is still in a phase I/IIa trial for Prostate cancer in USA
- 31 Aug 2011 Phase-I/II clinical trials in Prostate cancer (late-stage disease, second-line therapy or greater) in USA (PO)